Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aeterna Zentaris inks licensing deal with Hikma for Perifosine in MENA
Perifosine is an oral anticancer treatment that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway. The drug is in two Phase 3 programs for the treatment of
Perifosine is an oral anticancer treatment that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway. The drug is in two Phase 3 programs for the treatment of
Alogliptin is a selective dipeptidyl peptidase IV inhibitor (DPP-4i) which is being evaluated in the US to treat type 2 diabetes as an adjunct to diet and exercise.
By adopting IBM Initiate, DB2, Cognos, and WebSphere software into its MEDxConnect platform, Compressus intends to look into the issue of interoperability. MEDxConnect provides an easy way to
Intermezzo is available in doses of 1.75 mg and 3.5 mg as a sublingual tablet that contains a bicarbonate-carbonate buffer. The approval is backed by two placebo-controlled studies
According to the company, the BD MAX MRSA Assay is designed to be used on BD MAX automated molecular system to rapidly identify methicillin-resistant Staphylococcus aureus (MRSA) in
VPRIV is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy in patients with type 1 Gaucher disease. The company hopes to increase the production capacity
Arcalyst is used to treat Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). The sBLA submission for Arcalyst is backed by positive
EpiCor is a natural product that helps in the maintenance of the immune system. The clinical studies have demonstrated EpiCor’s immune-balancing properties in helping the body boost or
pSivida is independently developing a product to treat uveitis affecting the posterior segment of the eye (posterior uveitis). In addition, the company has partnered with Pfizer for the
Vascazen is used to treat patients with Omega-3 fatty acids deficiency. Pivotal Therapeutics president Rachelle MacSweeney said the launch of Vascazen in North America is a key milestone